Nous-209 neoantigen vaccine for cancer prevention in Lynch Syndrome carriers: a phase 1b/2 trial
Nous-209 neoantigen vaccine for cancer prevention in Lynch Syndrome carriers: a phase 1b/2 trial
Elisa Scarselli, Direttore scientifico e cofondatore Nouscom Srl, terrà un seminario dal titolo "